Aprindine (AC 1802), a new anti-arrhythmic drug.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001281:Atrial Fibrillation / Q000188:drug therapy; D001282:Atrial Flutter / Q000188:drug therapy; D005117:Cardiac Complexes, Premature / Q000188:drug therapy; D002986:Clinical Trials as Topic; D005021:Ethylamines / Q000008:administration & dosage / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D006327:Heart Block / Q000188:drug therapy; D006801:Humans; D007192:Indenes / Q000008:administration & dosage / Q000627:therapeutic use*; D007267:Injections; D008875:Middle Aged; D008946:Mitral Valve Stenosis / Q000188:drug therapy; D009203:Myocardial Infarction / Q000188:drug therapy; D011437:Propylamines / Q000008:administration & dosage / Q000627:therapeutic use; D013610:Tachycardia / Q000188:drug therapy; D014717:Vertigo / Q000139:chemically induced; D014927:Wolff-Parkinson-White Syndrome / Q000188:drug therapy
D000889:Anti-Arrhythmia Agents; D005021:Ethylamines; D007192:Indenes; D011437:Propylamines